- TRADE NAME: Spinraza (Biogen)
- INDICATIONS: Spinal muscular atrophy
- CLASS: Survival motor neuron-2 (SMN2)-directed antisense oligonucleotide
- HALF-LIFE: 63–87 days (in plasma)
- FDA APPROVAL DATE: 12/23/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No data available
Please login to view the rest of this drug profile.
Page last updated 02/17/2024
